{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T09:38:49Z","timestamp":1792834729958,"version":"4.5.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"35","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,28]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Acyclovir is the first-line treatment for neonatal herpes simplex virus infection; however, safety evidence in neonates remains limited. This study aimed to evaluate the safety profile of acyclovir in neonates using real-world pharmacovigilance data from the Food and Drug Administration Adverse Event Reporting System. This retrospective observational study analyzed adverse event (AE) reports in neonates (\u226428 days) in which acyclovir was identified as the primary suspected drug in the Food and Drug Administration Adverse Event Reporting System from 2004 to Q3 2024. Disproportionality analyses were performed using the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network, and empirical Bayesian geometric mean (EBGM). Positive risk signals were defined as those meeting the statistical significance criteria across all 4 methods. A total of 130 reports comprising 409 AEs were identified. Four system organ classes showed positive risk signals: skin and subcutaneous tissue disorders (ROR\u2005=\u20056.22, PRR\u2005=\u20055.88, lower limit of 95% confidence interval [CI] of the information component [IC025]\u2005=\u20051.98, lower limit of 95% CI of EBGM [EBGM05]\u2005=\u20054.16), general disorders and administration site conditions (ROR\u2005=\u20054.27, PRR\u2005=\u20053.47, IC025\u2005=\u20051.47, EBGM05\u2005=\u20052.85), hepatobiliary disorders (ROR\u2005=\u20053.85, PRR\u2005=\u20053.74, IC025\u2005=\u20051.19, EBGM05\u2005=\u20052.43), and renal and urinary disorders (ROR\u2005=\u20053.84, PRR\u2005=\u20053.70, IC025\u2005=\u20051.24, EBGM05\u2005=\u20052.51). At the preferred term level, 12 positive signals were detected, with the strongest signals observed for infusion site necrosis\/edema (ROR\u2005=\u2005939.92, 95% CI: 97.56\u20139055.25), arthritis (ROR\u2005=\u2005179.47, 95% CI: 52.33\u2013615.44), skin exfoliation\/necrosis (ROR\u2005=\u2005131.18, 95% CI: 46.00\u2013374.06), and Kawasaki disease (ROR\u2005=\u2005114.20, 95% CI: 36.21\u2013360.15). Notably, Kawasaki disease, rectal hemorrhage, and necrotizing colitis were not described in existing product labeling. Acyclovir use in neonates may be associated with immune, gastrointestinal, hepatic, and renal AEs, underscoring the need for careful clinical monitoring. Further prospective studies are warranted to validate these associations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050426","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T02:00:20Z","timestamp":1787968820000},"page":"e50426","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Safety analysis of acyclovir use in neonates based on the FDA Adverse Event Reporting System"],"prefix":"10.1097","volume":"105","author":[{"given":"Longbing","family":"He","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Suqian First Hospital, Suqian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8916-3049","authenticated-orcid":false,"given":"Bo","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Suqian First Hospital, Suqian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Affiliated Huaihai Hospital of Xuzhou Medical University, Xuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1084-9568","authenticated-orcid":false,"given":"Youshuai","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Fourth Affiliated Hospital of Nanjing Medical University, Nanjing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261024","doi-asserted-by":"crossref","first-page":"102040","DOI":"10.1016\/j.japh.2024.02.013","article-title":"Acyclovir dosing in herpes encephalitis: a scoping review.","volume":"64","author":"Aboelezz","year":"2024","journal-title":"J Am Pharm Assoc (2003)"},{"key":"R2-20261024","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s10096-018-3332-5","article-title":"Incidence and predictors of intravenous acyclovir-induced nephrotoxicity.","volume":"37","author":"Richelsen","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R3-20261024","doi-asserted-by":"crossref","first-page":"6566","DOI":"10.3390\/molecules26216566","article-title":"Critical review of synthesis, toxicology and detection of acyclovir.","volume":"26","author":"Wei","year":"2021","journal-title":"Molecules"},{"key":"R4-20261024","doi-asserted-by":"crossref","first-page":"e1193","DOI":"10.1002\/prp2.1193","article-title":"Population pharmacokinetics and dose rationale for aciclovir in term and pre-term neonates with herpes.","volume":"12","author":"D\u2019Agate","year":"2024","journal-title":"Pharmacol Res Perspect"},{"key":"R5-20261024","doi-asserted-by":"crossref","first-page":"e1012935","DOI":"10.1371\/journal.ppat.1012935","article-title":"Asymptomatic neonatal herpes simplex virus infection in mice leads to persistent CNS infection and long-term cognitive impairment.","volume":"21","author":"Dutton","year":"2025","journal-title":"PLoS Pathog"},{"key":"R6-20261024","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.3346\/jkms.2025.40.e282","article-title":"A multicenter study on symptomatic neonatal herpes simplex virus infection in Korea from 2008 to 2017.","volume":"40","author":"Kim","year":"2025","journal-title":"J Korean Med Sci"},{"key":"R7-20261024","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/OLQ.0000000000002259","article-title":"Neonatal herpes simplex virus infection in the United States: regional and time trends, 2017\u20132021.","volume":"53","author":"Lewis","year":"2026","journal-title":"Sex Transm Dis"},{"key":"R8-20261024","doi-asserted-by":"crossref","first-page":"105616","DOI":"10.1016\/j.earlhumdev.2022.105616","article-title":"Exposure-safety relationship for acyclovir in the treatment of neonatal herpes simplex virus disease.","volume":"170","author":"Ericson","year":"2022","journal-title":"Early Hum Dev"},{"key":"R9-20261024","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/QCO.0000000000001043","article-title":"Universal versus targeted treatment of neonatal herpes simplex virus among neonates presenting for sepsis evaluations.","volume":"37","author":"Dantuluri","year":"2024","journal-title":"Curr Opin Infect Dis"},{"key":"R10-20261024","first-page":"490","article-title":"Clinical review of risk of nephrotoxicity with acyclovir use for treatment of herpes simplex virus infections in neonates and children.","volume":"28","author":"ElHassan","year":"2023","journal-title":"J Pediatr Pharmacol Ther"},{"key":"R11-20261024","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s40272-014-0066-4","article-title":"Standard-dose versus high-dose acyclovir in children treated empirically for encephalitis: a retrospective cohort study of its use and safety.","volume":"16","author":"Kendrick","year":"2014","journal-title":"Paediatr Drugs"},{"key":"R12-20261024","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/17512433.2023.2294002","article-title":"Signal mining study of severe cutaneous adverse events of valaciclovir or acyclovir based on the FAERS database.","volume":"17","author":"Mao","year":"2024","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R13-20261024","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/0886022X.2018.1487866","article-title":"The incidence, risk factors, and clinical outcomes of acute kidney injury (staged using the RIFLE classification) associated with intravenous acyclovir administration.","volume":"40","author":"Lee","year":"2018","journal-title":"Ren Fail"},{"key":"R14-20261024","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2174\/1574886313666181026100000","article-title":"Novel adverse events of iloperidone: a disproportionality analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) database.","volume":"14","author":"Subeesh","year":"2019","journal-title":"Curr Drug Saf"},{"key":"R15-20261024","doi-asserted-by":"crossref","first-page":"19555","DOI":"10.1038\/s41598-022-23834-1","article-title":"A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.","volume":"12","author":"Yin","year":"2022","journal-title":"Sci Rep"},{"key":"R16-20261024","doi-asserted-by":"crossref","first-page":"2208891","DOI":"10.1080\/16078454.2023.2208891","article-title":"Establishment and validation of haematological reference intervals for newborns aged 5 to 28 days in Nanjing, China.","volume":"28","author":"Li","year":"2023","journal-title":"Hematology"},{"key":"R17-20261024","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/JS9.0000000000003538","article-title":"Artificial intelligence-driven pharmacovigilance analysis of polypharmacy and adverse events in breast cancer survivors treated with antidepressants.","volume":"112","author":"Zhang","year":"2026","journal-title":"Int J Surg"},{"key":"R18-20261024","doi-asserted-by":"crossref","first-page":"7489","DOI":"10.1038\/s41598-024-57909-y","article-title":"Signal mining and risk analysis of alprazolam adverse events based on the FAERS database.","volume":"14","author":"Huang","year":"2024","journal-title":"Sci Rep"},{"key":"R19-20261024","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/17512433.2024.2306223","article-title":"Metformin adverse event profile: a pharmacovigilance study based on the FDA Adverse Event Reporting System (FAERS) from 2004 to 2022.","volume":"17","author":"Du","year":"2024","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R20-20261024","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","article-title":"Safety assessment of brexpiprazole: real-world adverse event analysis from the FAERS database.","volume":"346","author":"Jiang","year":"2024","journal-title":"J Affect Disord"},{"key":"R22-20261024","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/cei.12832","article-title":"Kawasaki disease: a matter of innate immunity.","volume":"186","author":"Hara","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"R23-20261024","doi-asserted-by":"crossref","first-page":"e1284","DOI":"10.1002\/cti2.1284","article-title":"The up-to-date pathophysiology of Kawasaki disease.","volume":"10","author":"Hara","year":"2021","journal-title":"Clin Transl Immunology"},{"key":"R24-20261024","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11926-015-0545-9","article-title":"Drug-induced vasculitis: new insights and a changing lineup of suspects.","volume":"17","author":"Grau","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"R25-20261024","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.24976\/Discov.Med.202436187.150","article-title":"Anti-inflammatory immunomodulatory activity of valacyclovir on the in vitro activated mammalian macrophages.","volume":"36","author":"Aydemir","year":"2024","journal-title":"Discov Med"},{"key":"R26-20261024","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/bs.apha.2018.12.001","article-title":"Mechanisms of idiosyncratic drug-induced liver injury.","volume":"85","author":"Uetrecht","year":"2019","journal-title":"Adv Pharmacol"},{"key":"R27-20261024","first-page":"4099","article-title":"The effects and pharmacokinetics of acyclovir in neonates.","volume":"4","author":"Pacifici","year":"2016","journal-title":"Int J Pediatr"},{"key":"R28-20261024","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1046\/j.1365-2036.1997.147323000.x","article-title":"Acyclovir-induced colitis.","volume":"11","author":"Wardle","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"R29-20261024","first-page":"3417","article-title":"Acyclovir-induced immune thrombocytopenia: case report and review of the literature.","volume":"20","author":"Fekete","year":"2020","journal-title":"Exp Ther Med"},{"key":"R30-20261024","doi-asserted-by":"crossref","first-page":"32","DOI":"10.5005\/jp-journals-11002-0003","article-title":"Intestinal epithelial barrier function and necrotizing enterocolitis.","volume":"1","author":"Managlia","year":"2022","journal-title":"Newborn (Clarksville)"},{"key":"R31-20261024","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.siny.2018.08.008","article-title":"Intestinal microcirculation and necrotizing enterocolitis: the vascular endothelial growth factor system.","volume":"23","author":"Bowker","year":"2018","journal-title":"Semin Fetal Neonatal Med"},{"key":"R32-20261024","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.arcped.2007.08.013","article-title":"Necrotizing enterocolitis in a full-term infant. Is acyclovir involved?","volume":"14","author":"Montjaux-R\u00e9gis","year":"2007","journal-title":"Arch Pediatr"},{"key":"R33-20261024","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1080\/14740338.2024.2412235","article-title":"Differences in safety profiles of anti-herpesvirus medications: a real-world pharmacovigilance study based on the FAERS database.","volume":"24","author":"He","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"R34-20261024","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jpeds.2019.12.056","article-title":"Acute kidney injury during treatment with intravenous acyclovir for suspected or confirmed neonatal herpes simplex virus infection.","volume":"219","author":"Downes","year":"2020","journal-title":"J Pediatr"},{"key":"R35-20261024","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.yrtph.2008.02.005","article-title":"Renal clearance parameters for PBPK model analysis of early lifestage differences in the disposition of environmental toxicants.","volume":"51","author":"DeWoskin","year":"2008","journal-title":"Regul Toxicol Pharmacol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050426","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T09:00:54Z","timestamp":1792832454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050426"}},"subtitle":["A retrospective observational pharmacovigilance study"],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":34,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050426","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"assertion":[{"value":"2026-02-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}